This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Astellas Pharma, Inc.

Drug Names(s): Adeno-associated Virus-modified Volvox channelrhodopsin-1

Description: AAV-mVChR1 is an Adeno-associated Virus vector carrying the mVChR1 gene, a modified Volvox channelrhodopsin-1. Channelrhodopsins are photoreceptive ion channels and mVChR1 was engineered to respond to broad wavelengths of lights. Expressed in retinal ganglion cells, mVChR1 may restore some visual function to patients with retinitis pigmentosa.

Deal Structure: CLINO and Astellas
In February 2016, Astellas Pharma and CLINO Corporation announced that Astellas and CLINO have entered into a license agreement for the worldwide development and commercialization of Adeno-associated Virus-modified Volvox channelrhodopsin-1 (AAV-mVChR1) to treat retinitis pigmentosa. Financial details were not disclosed.

Partners: CLINO Corporation

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug